Eli Lilly and Company (LLY) shares rose nearly 4% on Monday, kicking off the week on a positive note. The share price increase followed the approval of one of the company’s flagship drugs by a major European regulatory authority. The news also brought optimistic sentiment to the weight-loss drug market, which has continued to surge in recent years.
The approved product is Eli Lilly’s Foundayo, the company’s first oral weight-loss medication (note that this is distinct from its injectable obesity treatment, Zepbound). On Monday, the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) approved Foundayo for weight management and the treatment of type 2 diabetes. This makes the United Kingdom the first European country to authorize the oral drug for market use.
However, similar to the situation in the U.S. market, Foundayo is not the first oral weight-loss drug available in the U.K. Its competitor, Novo Nordisk (NVO), received MHRA approval for its oral Wegovy in June of this year, and it is currently available to U.K. patients.
While being first to market typically offers significant advantages, analysts believe that Eli Lilly, as a market follower, will not suffer substantial losses. First, Eli Lilly possesses extensive commercial infrastructure and can allocate substantial resources to promote its products to local consumers. Second, demand in the obesity treatment market is robust; even in the U.K., with a population of nearly 60 million, the second entrant can still generate considerable sales revenue. Finally, this is only Eli Lilly’s first approval in Europe, and the European market is vast. Although obesity is less prevalent in Europe than in the United States, the potential patient population remains quite substantial.
As a large-scale pharmaceutical company, Eli Lilly’s business extends beyond weight-loss drugs. Regardless, securing U.K. regulatory approval in this persistently high-demand product category is unequivocally positive news, making it a reasonable catalyst for the share price increase.
Eli Lilly also recently announced that it plans to submit a marketing application for retatrutide to the U.S. Food and Drug Administration (FDA) in the first quarter of 2027. This new product is expected to help Eli Lilly expand its lead over its biggest competitor, Novo Nordisk, in the weight-loss arena.
In Phase 3 clinical trials, retatrutide achieved an average weight reduction of up to 28.3% in patients over 80 weeks. This efficacy not only significantly outperforms Novo Nordisk’s Wegovy in clinical trial results but has also been noted by some analysts as being comparable to bariatric surgery. Currently, no other weight-loss drug has demonstrated efficacy that surpasses or matches retatrutide, including Zepbound. Furthermore, retatrutide has also achieved significant weight loss in patients with diabetes, a population that typically finds it more difficult to lose weight.
Beyond obesity and diabetes, retatrutide is also being studied for indications including obstructive sleep apnea, chronic back pain, and metabolic dysfunction-associated steatohepatitis. Eli Lilly has expanded and enriched its research and development pipeline, with the potential for significant progress in other markets such as oncology and immunology in the coming years. In short, Eli Lilly has no intention of relinquishing its leading position in weight loss while also aiming to dominate other therapeutic areas. The company’s sustained success is likely to deliver solid returns over the medium term. For Novo Nordisk and other pharmaceutical giants hoping to challenge Eli Lilly, this is undoubtedly a clear signal.
